Cargando…
Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effect...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378587/ https://www.ncbi.nlm.nih.gov/pubmed/22723841 http://dx.doi.org/10.1371/journal.pone.0037980 |
_version_ | 1782236063179210752 |
---|---|
author | Riccio, Anna Maria Saverino, Daniele Pesce, Giampaola Rogkakou, Anthi Severino, Maurizio Bonadonna, Patrizia Ridolo, Erminia Mauro, Marina Canonica, Giorgio Walter Bagnasco, Marcello Passalacqua, Giovanni |
author_facet | Riccio, Anna Maria Saverino, Daniele Pesce, Giampaola Rogkakou, Anthi Severino, Maurizio Bonadonna, Patrizia Ridolo, Erminia Mauro, Marina Canonica, Giorgio Walter Bagnasco, Marcello Passalacqua, Giovanni |
author_sort | Riccio, Anna Maria |
collection | PubMed |
description | BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day). METHODS: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance. RESULTS: Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values. CONCLUSIONS: Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment. |
format | Online Article Text |
id | pubmed-3378587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33785872012-06-21 Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 Riccio, Anna Maria Saverino, Daniele Pesce, Giampaola Rogkakou, Anthi Severino, Maurizio Bonadonna, Patrizia Ridolo, Erminia Mauro, Marina Canonica, Giorgio Walter Bagnasco, Marcello Passalacqua, Giovanni PLoS One Research Article BACKGROUND: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy. OBJECTIVE: to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day). METHODS: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance. RESULTS: Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values. CONCLUSIONS: Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment. Public Library of Science 2012-06-19 /pmc/articles/PMC3378587/ /pubmed/22723841 http://dx.doi.org/10.1371/journal.pone.0037980 Text en Riccio et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Riccio, Anna Maria Saverino, Daniele Pesce, Giampaola Rogkakou, Anthi Severino, Maurizio Bonadonna, Patrizia Ridolo, Erminia Mauro, Marina Canonica, Giorgio Walter Bagnasco, Marcello Passalacqua, Giovanni Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title | Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title_full | Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title_fullStr | Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title_full_unstemmed | Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title_short | Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10 |
title_sort | effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and il-10 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378587/ https://www.ncbi.nlm.nih.gov/pubmed/22723841 http://dx.doi.org/10.1371/journal.pone.0037980 |
work_keys_str_mv | AT riccioannamaria effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT saverinodaniele effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT pescegiampaola effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT rogkakouanthi effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT severinomaurizio effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT bonadonnapatrizia effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT ridoloerminia effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT mauromarina effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT canonicagiorgiowalter effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT bagnascomarcello effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT passalacquagiovanni effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 |